Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical Trials

IMPORTANCE: Development of effective, scalable therapeutics for SARS-CoV-2 is a priority. OBJECTIVE: To test the efficacy of combined tixagevimab and cilgavimab monoclonal antibodies for early COVID-19 treatment. DESIGN, SETTING, AND PARTICIPANTS: Two phase 2 randomized blinded placebo-controlled cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Bender Ignacio, Rachel A., Chew, Kara W., Moser, Carlee, Currier, Judith S., Eron, Joseph J., Javan, Arzhang Cyrus, Giganti, Mark J., Aga, Evgenia, Gibbs, Michael, Tchouakam Kouekam, Hervé, Johnsson, Eva, Esser, Mark T., Hoover, Keila, Neytman, Gene, Newell, Matthew, Daar, Eric S., Fischer, William, Fletcher, Courtney V., Li, Jonathan Z., Greninger, Alexander L., Coombs, Robert W., Hughes, Michael D., Smith, Davey, Wohl, David Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134004/
https://www.ncbi.nlm.nih.gov/pubmed/37099295
http://dx.doi.org/10.1001/jamanetworkopen.2023.10039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134004/
https://www.ncbi.nlm.nih.gov/pubmed/37099295
http://dx.doi.org/10.1001/jamanetworkopen.2023.10039

Ejemplares similares